Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancerTakashi Nomizo, Hideo Kita, Tsunetaka Murayama et al.|Trends in Immunotherapy|2022Cited by 1